Cargando…

Newborn Mice Vaccination with BCG.HIVA(222) + MVA.HIVA Enhances HIV-1-Specific Immune Responses: Influence of Age and Immunization Routes

We have evaluated the influence of age and immunization routes for induction of HIV-1- and M. tuberculosis-specific immune responses after neonatal (7 days old) and adult (7 weeks old) BALB/c mice immunization with BCG.HIVA(222) prime and MVA.HIVA boost. The specific HIV-1 cellular immune responses...

Descripción completa

Detalles Bibliográficos
Autores principales:	Saubi, Narcís, Im, Eung-Jun, Fernández-Lloris, Raquel, Gil, Olga, Cardona, Pere-Joan, Gatell, Josep Maria, Hanke, Tomáš, Joseph, Joan
Formato:	Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2011
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3095426/ https://www.ncbi.nlm.nih.gov/pubmed/21603216 http://dx.doi.org/10.1155/2011/516219

Ejemplares similares

P17-17. Newborn mice vaccination with rBCG:HIVA + MVA:HIVA enhances HIV-1-specific immune responses. Influence of age and immunization routes
por: Saubi, N, et al.
Publicado: (2009)

Pre-Clinical Development of BCG.HIVA(CAT), an Antibiotic-Free Selection Strain, for HIV-TB Pediatric Vaccine Vectored by Lysine Auxotroph of BCG
por: Saubi, Narcís, et al.
Publicado: (2012)

Preclinical development of BCG.HIVA(2auxo.int), harboring an integrative expression vector, for a HIV-TB Pediatric vaccine. Enhancement of stability and specific HIV-1 T-cell immunity
por: Mahant, Aakash, et al.
Publicado: (2017)

Pre-clinical development of BCG.HIVA(CAT) strain, an antibiotic-free selection strain for HIV-TB pediatric vaccine
por: Saubi, N, et al.
Publicado: (2012)

A Phase I Randomized Clinical Trial of Candidate Human Immunodeficiency Virus type 1 Vaccine MVA.HIVA Administered to Gambian Infants
por: Afolabi, Muhammed O., et al.
Publicado: (2013)

PedVacc 002: A phase I/II randomized clinical trial of MVA.HIVA vaccine administered to infants born to human immunodeficiency virus type 1-positive mothers in Nairobi
por: Njuguna, Irene N., et al.
Publicado: (2014)

Molecular Characterization of Heterologous HIV-1gp120 Gene Expression Disruption in Mycobacterium bovis BCG Host Strain: A Critical Issue for Engineering Mycobacterial Based-Vaccine Vectors
por: Joseph, Joan, et al.
Publicado: (2010)

Priming with Recombinant BCG Expressing HTI Enhances the Magnitude and Breadth of the T-Cell Immune Responses Elicited by MVA.HTI in BALB/c Mice
por: Saubi, Narcís, et al.
Publicado: (2020)

Lost bioscapes: Floristic and arthropod diversity coincident with 12(th) century Polynesian settlement, Nuku Hiva, Marquesas Islands
por: Allen, Melinda S., et al.
Publicado: (2022)

Engineering new mycobacterial vaccine design for HIV–TB pediatric vaccine vectored by lysine auxotroph of BCG
por: Saubi, Narcís, et al.
Publicado: (2014)

Toxicological Investigations on the Sea Urchin Tripneustes gratilla (Toxopneustidae, Echinoid) from Anaho Bay (Nuku Hiva, French Polynesia): Evidence for the Presence of Pacific Ciguatoxins
por: Darius, Hélène Taiana, et al.
Publicado: (2018)

Assessment of Ciguatera and Other Phycotoxin-Related Risks in Anaho Bay (Nuku Hiva Island, French Polynesia): Molecular, Toxicological, and Chemical Analyses of Passive Samplers
por: Roué, Mélanie, et al.
Publicado: (2020)

Tectus niloticus (Tegulidae, Gastropod) as a Novel Vector of Ciguatera Poisoning: Detection of Pacific Ciguatoxins in Toxic Samples from Nuku Hiva Island (French Polynesia)
por: Darius, Hélène Taiana, et al.
Publicado: (2017)

Tectus niloticus (Tegulidae, Gastropod) as a Novel Vector of Ciguatera Poisoning: Clinical Characterization and Follow-Up of a Mass Poisoning Event in Nuku Hiva Island (French Polynesia)
por: Gatti, Clémence Mahana iti, et al.
Publicado: (2018)

Recombinant BCG Expressing HTI Prime and Recombinant ChAdOx1 Boost Is Safe and Elicits HIV-1-Specific T-Cell Responses in BALB/c Mice
por: Kilpeläinen, Athina, et al.
Publicado: (2019)

Priming With Recombinant BCG Expressing Novel HIV-1 Conserved Mosaic Immunogens and Boosting With Recombinant ChAdOx1 Is Safe, Stable, and Elicits HIV-1-Specific T-Cell Responses in BALB/c Mice
por: Kilpeläinen, Athina, et al.
Publicado: (2019)

Multiple Consecutive Infections Might Explain the Lack of Protection by BCG
por: Cardona, Pere-Joan, et al.
Publicado: (2014)

Chimeric Human Papillomavirus-16 Virus-like Particles Presenting P18I10 and T20 Peptides from HIV-1 Envelope Induce HPV16 and HIV-1-Specific Humoral and T Cell-Mediated Immunity in BALB/c Mice
por: Chen, Chun-Wei, et al.
Publicado: (2022)

MVA85A vaccine to enhance BCG for preventing tuberculosis
por: Kashangura, Rufaro, et al.
Publicado: (2019)

Evaluation of a Human BCG Challenge Model to Assess Antimycobacterial Immunity Induced by BCG and a Candidate Tuberculosis Vaccine, MVA85A, Alone and in Combination
por: Harris, Stephanie A., et al.
Publicado: (2014)

Design Concepts of Virus-Like Particle-Based HIV-1 Vaccines
por: Chen, Chun-Wei, et al.
Publicado: (2020)

Chimeric Human Papillomavirus-16 Virus-like Particles Presenting HIV-1 P18I10 Peptide: Expression, Purification, Bio-Physical Properties and Immunogenicity in BALB/c Mice
por: Chen, Chun-Wei, et al.
Publicado: (2023)

Expression of Chimeric HPV-HIV Protein L1P18 in Pichia pastoris; Purification and Characterization of the Virus-like Particles
por: Eto, Yoshiki, et al.
Publicado: (2021)

Safety and vaccine-induced HIV-1 immune responses in healthy volunteers following a late MVA-B boost 4 years after the last immunization
por: C. Guardo, Alberto, et al.
Publicado: (2017)

Safety and Immunogenicity of Boosting BCG Vaccinated Subjects with BCG: Comparison with Boosting with a New TB Vaccine, MVA85A
por: Whelan, Kathryn T., et al.
Publicado: (2009)

Correction: Safety and vaccine-induced HIV-1 immune responses in healthy volunteers following a late MVA-B boost 4 years after the last immunization
por: Guardo, Alberto C., et al.
Publicado: (2018)

Correction: Safety and Immunogenicity of Boosting BCG Vaccinated Subjects with BCG: Comparison with Boosting with a New TB Vaccine, MVA85A
por: Whelan, Kathryn T., et al.
Publicado: (2011)

A prime-boost immunization with rBCG expressing HIV-1 Gag, RT and gp120 and SAAVI MVA-C elicits immune responses in blood and MALT of rhesus macaques
por: Chege, GK, et al.
Publicado: (2012)

Immune Profiles Identification by Vaccinomics After MVA Immunization in Randomized Clinical Study
por: Sanchez, Jorge, et al.
Publicado: (2020)

P19-53 LB. Priming with recombinant BCG expressing HIV-1 Gag or RT and boosting with recombinant MVA induces an effective immune response in mice
por: Stutz, H, et al.
Publicado: (2009)

Complete Genome Sequence of Mycobacterium bovis BCG SL222 Sofia, the First WHO Reference Reagent for the M. bovis BCG Vaccine of the Russian BCG-I Substrain
por: Panaiotov, Stefan, et al.
Publicado: (2021)

Boosting BCG vaccination with MVA85A down-regulates the immunoregulatory cytokine TGF-β1
por: Fletcher, Helen A., et al.
Publicado: (2008)

Drosophila melanogaster as a model to study innate immune memory
por: Arch, Marta, et al.
Publicado: (2022)

Comparison of Safety and Vector-Specific Immune Responses in Healthy and HIV-Infected Populations Vaccinated with MVA-B
por: Couto, Elvira, et al.
Publicado: (2019)

The Humoral Immune Response to BCG Vaccination
por: Tanner, Rachel, et al.
Publicado: (2019)

Persistence of the immune response induced by BCG vaccination
por: Weir, Rosemary E, et al.
Publicado: (2008)

Modulation of the immune response by BCG: a review.
por: Murahata, R. I., et al.
Publicado: (1976)

Immunometabolic Pathways in BCG-Induced Trained Immunity
por: Arts, Rob J.W., et al.
Publicado: (2016)

Cross-reactive immune responses to monkeypox virus induced by MVA vaccination in mice
por: Gao, Feixia, et al.
Publicado: (2023)

A multi-antigenic MVA vaccine increases efficacy of combination chemotherapy against Mycobacterium tuberculosis
por: Leung-Theung-Long, Stéphane, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_g952d819usuutc56lu9igha3i2